Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05642754
Other study ID # 557972
Secondary ID CPHS 32615
Status Completed
Phase N/A
First received
Last updated
Start date December 1, 2022
Est. completion date March 31, 2023

Study information

Verified date May 2024
Source Trustees of Dartmouth College
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Randomized trial testing 6 forms of a communication summarizing the results of a recent study (about the effects of wearing glasses on reducing covid infection risk). The goal of the trial is to test the effect of different language options to describe uncertainty, and of including the margin of error around the main result.


Description:

The study is designed as a proof-of-concept exercise to develop and test a communication meant to summarize the results of a recent randomized trial examining the effects of wearing glasses on the chance of developing COVID-19. The objectives of the randomized trial are: - To compare the effects of three ways of communicating the overall uncertainty of the effects of wearing glasses to reduce the chance of getting COVID and - To compare the effects of including the margin of error (confidence interval) compared to not including it. Researchers will conduct an online, parallel group, individually randomized, pragmatic trial using a 3x2 factorial design, ie, 3 uncertainly language options (GRADE language, colloquial language or none 2 options for the statistical margin of error for the main results (margin of error language or none).


Recruitment information / eligibility

Status Completed
Enrollment 960
Est. completion date March 31, 2023
Est. primary completion date January 31, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - >= 18 years old - literate in English or Norwegian - currently residing in Norway or the United States Exclusion Criteria: - individuals who regularly wear any kind of glasses (i.e., prescription or sunglasses) all or most of the time

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Overall uncertainty language
Researchers are testing different forms of information about overall study uncertainty and margin of error around main result

Locations

Country Name City State
Norway Norwegian Institute of Public Health Oslo

Sponsors (2)

Lead Sponsor Collaborator
Trustees of Dartmouth College Norwegian Institute of Public Health

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary understanding of overall uncertainty of benefit (of wearing glasses to reduce the chance of covid infection) How sure about the effect (4 point scale from very unsure to very sure) within 1 day
Primary understanding of overall uncertainty of harm (of wearing glasses to reduce the chance of covid infection) How sure about the effect (4 point scale from very unsure to very sure) within 1 day
Primary sufficiency of what is known about the effects of wearing glasses to reduce the chance of covid infection How sure about the effect (4 point Likert scale) within 1 day
Primary Understanding the margin of error around the benefit of wearing glasses to reduce covid this is a co-primary outcome which will be used only to compare the 3 versions that include the margin of error to the 3 versions that do not within 1 day
Secondary perceived effect of wearing glasses to reduce chance of covid infection What is the effect on a 5 point scale (lowers a lot, lowers a little, no effect, increase a little, increases a lot within 1 day
Secondary how likely is it that wearing glasses reduces the chance of covid infection 4 point scale (very likely, likely, unlikely, very unlikely) within 1 day
Secondary intended behavior (if there were a surge in covid in your area, how likely would you be to wear glasses to reduce the chance of covid infection 4 point scale (very likely, likely, unlikely, very unlikely within 1 day
Secondary intended behavior (if there were very few cases of covid in your area, how likely would you be to wear glasses to reduce the chance of covid infection 4 point scale (very likely, likely, unlikely, very unlikely within 1 day
Secondary perceptions fo information provided (trustworthy summary?) 4 point Likert scale (strongly agree, agree, disagree, strongly disagree) within 1 day
Secondary perceptions fo information provided (sufficient summary?) 4 point Likert scale (strongly agree, agree, disagree, strongly disagree) within 1 day
Secondary perceptions fo information provided (clarity of info about benefit) 4 point scale (very clear, clear, unclear, very unclear) within 1 day
Secondary perceptions fo information provided (clarity of info about harm) 4 point scale (very clear, clear, unclear, very unclear) within 1 day
Secondary perceptions fo information provided (info helpful?) 4 point scale (very helpful, helpful, unhelpful, very unhelpful) within 1 day
Secondary perceptions fo information provided (share info with others?) 4 point scale (definitely yes, probably yes, probably no, definitely no) within 1 day
Secondary Decisional conflict (hard to make decision) 4 point LIkert scale (strongly agree, agree, disagree, strongly disagree) within 1 day
Secondary Decisional conflict (made informed decision) 4 point LIkert scale (strongly agree, agree, disagree, strongly disagree) within 1 day
Secondary Decisional conflict (satisfied with decision) 4 point LIkert scale (strongly agree, agree, disagree, strongly disagree) within 1 day
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure